Abstract
1 The addition of furazolidone to the feed at the therapeutic level (0.04% w/w, 10 days) inhibited monoamine oxidase (MAO) activity by 47 to 72% in chicken duodenal mucosa, heart and brain, but in the liver the enzyme activity was unaffected by the treatment. 2 Furazolidone (200 mg/kg) administered by crop tube inhibited MAO activities in duodenal mucosa, liver, heart and brain. 3 Furazolidone (200 mg/kg) injected intramuscularly did not inhibit MAO activity in the chicken. 4 Pretreatment of the chickens with intramuscular neomycin did not antagonize the inhibition of MAO activity produced by furazolidone (200 mg/kg, crop tube). 5 Pretreatment with neomycin by crop tube to suppress the alimentary flora significantly reduced the effect of furazolidone on MAO activity, suggesting that the drug was transformed by the alimentary flora to an active metabolite which subsequently inhibited MAO activity in other organs. 6 Furazolidone in the feed (0.04% w/w, 10 days) or administered by crop tube (200 mg/kg) had no effect on the activity of aminopyrine demethylase in chicken liver. 7 The activity of aspartate transaminase in plasma was unaffected by the addition of furazolidone to the feed (0.04% w/w, 10 days).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- COOPER D. M., SKULSKI G. Effects of feeding furazolidone to fowls. I. Effect on body weight and sexual development in cockerels. J Comp Pathol. 1956 Oct;66(4):299–311. doi: 10.1016/s0368-1742(56)80032-5. [DOI] [PubMed] [Google Scholar]
- Century B., Rupp K. L. Comment on microfluorometric determination of monoamine oxidase. Biochem Pharmacol. 1968 Sep;17(9):2012–2013. doi: 10.1016/0006-2952(68)90121-4. [DOI] [PubMed] [Google Scholar]
- Ignarro L. J., Shideman F. E. Catechol-O-methyl transferase and monoamine oxidase activities in the heart and liver of the embryonic and developing chick. J Pharmacol Exp Ther. 1968 Jan;159(1):29–37. [PubMed] [Google Scholar]
- Kato R., Takanaka A., Shoji H. Inhibition of drug-metabolizing enzymes of liver microsomes by hydrazine derivatives in relation to their lipid solubility. Jpn J Pharmacol. 1969 Jun;19(2):315–322. doi: 10.1254/jjp.19.315. [DOI] [PubMed] [Google Scholar]
- Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol. 1965 Nov;14(11):1684–1686. doi: 10.1016/0006-2952(65)90025-0. [DOI] [PubMed] [Google Scholar]
- NASH T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J. 1953 Oct;55(3):416–421. doi: 10.1042/bj0550416. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pettinger W. A., Soyangco F. G., Oates J. A. Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther. 1968 Jul-Aug;9(4):442–447. doi: 10.1002/cpt196894442. [DOI] [PubMed] [Google Scholar]
- Staley N. A., Noren G. R., Bandt C. M., Sharp H. L. Furazolidone-induced cardiomyopathy in turkeys. Association with a relative alpha1-antitrypsin deficiency. Am J Pathol. 1978 Jun;91(3):531–544. [PMC free article] [PubMed] [Google Scholar]
- Stern I. J., Hollifield R. D., Wilk S., Buzard J. A. The anti-monoamine oxidase effects of furazolidone. J Pharmacol Exp Ther. 1967 Jun;156(3):492–499. [PubMed] [Google Scholar]
- Wilkinson J. H., Baron D. N., Moss D. W., Walker P. G. Standardization of clinical enzyme assays: a reference method for aspartate and alanine transaminases. J Clin Pathol. 1972 Nov;25(11):940–944. doi: 10.1136/jcp.25.11.940. [DOI] [PMC free article] [PubMed] [Google Scholar]